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Background The approval of 9-δ-tetrahydocannabinol
and cannabidiol (THC:CBD) oromucosal spray (Sativex)
for the management of treatment-resistant multiple
sclerosis (MS) spasticity opened a new opportunity for
many patients. The aim of our study was to describe
Sativex effectiveness and adverse events profile in a large
population of Italian patients with MS in the daily
practice setting.
Methods We collected data of all patients starting
Sativex between January 2014 and February 2015 from
the mandatory Italian medicines agency (AIFA) e-registry.
Spasticity assessment by the 0–10 numerical rating scale
(NRS) scale is available at baseline, after 1 month of
treatment (trial period), and at 3 and 6 months.
Results A total of 1615 patients were recruited from
30 MS centres across Italy. After one treatment month
(trial period), we found 70.5% of patients reaching a
≥20% improvement (initial response, IR) and 28.2%
who had already reached a ≥30% improvement
(clinically relevant response, CRR), with a mean NRS
score reduction of 22.6% (from 7.5 to 5.8). After a
multivariate analysis, we found an increased probability
to reach IR at the first month among patients with
primary and secondary progressive MS, (n=1169, OR 1.4
95% CI 1.04 to 1.9, p=0.025) and among patients with
>8 NRS score at baseline (OR 1.8 95% CI 1.3–2.4
p<0.001). During the 6 months observation period, 631
(39.5%) patients discontinued treatment. The main
reasons for discontinuation were lack of effectiveness
(n=375, 26.2%) and/or adverse events (n=268, 18.7%).
Conclusions Sativex can be a useful and safe option
for patients with MS with moderate to severe spasticity
resistant to common antispastic drugs.
INTRODUCTION
Spasticity, defined as abnormally increased muscu-
lar tone, is a common symptom in patients with
multiple sclerosis (MS) patients.1 MS spasticity
causes or worsens different MS symptoms, usually
having a big impact on patients’ quality of life.2
The most frequent symptoms associated with spas-
ticity in patients with MS, beyond mobility worsen-
ing, are spasms, pain, poor sleep quality (linked to
pain and nocturnal spasms) and urinary
dysfunction.3 Classically recommended medications
for generalised spasticity, including baclofen,
tizanidine, dantrolene, benzodiazepines and
clonazepam, have shown limited clinical benefit
in systematic reviews.4 5 The approval of
9-δ-tetrahydocannabinol and cannabidiol (THC:
CBD) oromucosal spray (Sativex), in a number of
European countries, including Italy, provides a new
opportunity as an add-on medication for the man-
agement of moderate to severe generalised spasti-
city and related symptoms in patients with MS
resistant to common oral antispastic drugs.6 7
Sativex is an endocannabinoid system modulator
containing THC and CBD in a near 1:1 ratio.
THC interacts with cannabinoid human receptors
that play a key role in the modulation of muscle
tone, whereas CBD at higher than natural concen-
trations may limit the psychoactive effects of
THC.8 The efficacy of Sativex oromucosal spray as
an add-on therapy for symptoms improvement in
patients with MS with moderate to severe MS spas-
ticity has been demonstrated in several clinical
trials.6 9–12 The largest pivotal phase III, enriched-
design clinical trial included patients with MS
with moderate–severe spasticity corresponding to
a patient-reported numerical rating scale (NRS)
score ≥4.
In this clinical trial, after a first 4 weeks single-
blind THC:CBD trial period, 47% of patients
showed an initial improvement in spasticity evalu-
ated by the MS spasticity 0–10 NRS scale (defined
as a ≥20% reduction vs baseline). During the
second phase, consisting of a double-blinded ran-
domisation of the initial responders to continue
either with THC:CBD treatment or placebo, a sig-
nificantly greater proportion of patients receiving
THC:CBD achieved a clinically relevant response
(defined as a ≥30% reduction in their baseline
NRS score). Almost 47% of patients reported
adverse events (AEs), with mild to moderate dizzi-
ness and fatigue being the most common
treatment-related adverse event.12 Although clinical
trials are needed to evaluate the efficacy and safety
of a new compound to defend its approval, obser-
vational studies are essential to depict the effect of
treatment in real-world conditions.13 Postapproval
surveillance registries have been established to





















evaluate possible short-term and long-term risks associated with
Sativex use.14 15 The MOVE 2 German observational study
(n>300) of THC:CBD oromucosal spray showed results aligned
with those from clinical trials, with 42% of patients being initial
responders after 4 weeks.16 Another recent prospective observa-
tional study carried out in Spain (n>200) provided data about
2/3 of patients still on prescription after 6 months from treat-
ment start.17 In these observational studies, patients tended to
use lower doses compared with clinical trials (6–7 sprays/day vs
>8) and the incidence of AEs was lower, with no evidence of
addiction, abuse, misuse or memory impairment.17 Given the
growing importance of data derived from real-world observa-
tional studies, we decided to collect information about Sativex
use in Italy, using the Italian medicine agency (AIFA) prospective
e-registry, mandatory for all patients receiving a Sativex prescrip-
tion in Italy, as a main source document, considering that, after
the large sample was collected, much larger than that in the
available THC:CBD studies so far, it would bring a comprehen-
sive picture of its effect, minimising biases. For further informa-
tion, we also used complementarily the involved patients’
medical charts retrospective review.
The main aim of our study was to describe Sativex effective-
ness and AEs, including possible evidence of abuse or misuse in
a large population of Italian patients with MS.
MATERIALS AND METHODS
Design and setting
This was a multicentre observational study aimed at collecting
prospective reported data to evaluate Sativex effects (effective-
ness and tolerability) in a large population of Italian patients
with MS with resistant spasticity carried out in a routine out-
patient setting. All patients included in the study were treated in
accordance with the approved label and expected standards of
good clinical practice. Complementary clinical and demographic
parameters were acquired retrospectively from the patients’
medical records.
The study was approved by the Policlinico-Vittorio Emanuele
(Catania, Italy) Ethics Committee (number 37/2015/PO) and by
the Ethics Committee of the other participating centres.
Patients were consecutively included in the study at the start
of Sativex treatment (baseline) and followed up over 6 months,
with data collection at baseline, after 4 weeks (T1), after
12 weeks (3 months, T2) and after 24 weeks (6 months, T3)
from baseline.
Patient population
The AIFA registry requests that patients are eligible for starting
Sativex treatment when fulfilling the following approved label-
related inclusion criteria: patients with MS older than 18 years,
with moderate to severe spasticity (0–10 NRS score ≥4) and not
responding to common and ongoing antispastic drugs (used
under their approved label). Exclusion criteria are: severe car-
diovascular diseases, history of psychiatric diseases, use of street
cannabis and/or other psychoactive drugs and/or MS spasticity
NRS score <4.
In our study, we collected data from all the patients starting
Sativex therapy between 1 January 2014 and end of February
2015 in the participating centres.
Data collection
We collected data from the AIFA Sativex e-registry website. The
MS spasticity evolution was evaluated by the validated 0–10
NRS patient-rated scale (0=no, 10=maximal spasticity).18 MS
physical disability was evaluated using the expanding disability
status scale (EDSS). Other parameters such as use of other anti-
spastic drug, previous antispastic drugs and treatment discon-
tinuation were collected.
Furthermore, complementary demographical and clinical
history data, tolerability, daily dose (number of puffs per day),
clinical response to Sativex, discontinuation reasons and time to
discontinuation, and improvement of spasticity-associated symp-
toms (stiffness, spasms/cramps, clonic movements, sleep distur-
bances, urinary dysfunctions, pain, depressed mood) were
collected from patients’ medical charts and using an ad hoc
interview. Data were manually entered in an ad hoc created
database. The following definitions were used for classifying
responses: Sativex effectiveness was evaluated through the initial
response (IR) threshold, defined as ≥20% NRS spasticity score
improvement versus the baseline value,18 and clinically relevant
response (CRR) threshold, defined as ≥30% NRS spasticity
score improvement versus baseline value.18 Tolerability was
assessed collecting each AE and serious adverse event (SAE)
occurring during the whole study period, in accordance with
the pharmacovigilance regulations.
STATISTICAL ANALYSIS
Data were analysed using the STATA V.11.0 software packages
(StataCorp. 2011. Stata Statistical Software: Release 12. College
Station TSL). Data cleaning was performed before the data ana-
lysis considering both range and consistence checks.
Quantitative variables were described using means and SDs.
The difference between means and the difference between pro-
portions was evaluated by the t test and the χ2 test, respectively.
A Shapiro-Wilk test was performed to assess the normal distribu-
tion of data. In case of a not normal distribution, appropriate
non-parametric tests were performed. Unconditional logistic
regression analysis was performed, and for each study variable
we calculated ORs, 95% CIs and p values (two-tailed p≤0.05
significant level). Univariate logistic regressions were fit consid-
ering binomial ‘IR yes/no’ as a dependent variable and age, sex,
disease duration, MS type, baseline EDSS and baseline NRS as
independent variables. Whenever quantitative variables were
dichotomised, the cut-offs were derived using the median.
Multivariate analysis was performed to investigate the independ-
ent effect of a risk or protective factor after adjustment for one
or several other factors or to adjust for confounding variables.
Parameters associated with the outcome in the univariate ana-




A total of 1615 patients with MS spasticity starting treatment
with Sativex were recruited from 30 large Italian MS centres
distributed geographically across the nation from about 160 spe-
cialised MS all-size centres in the country. Recruited patients
started treatment between 1 January 2014 and end of February
2015 (see table 1 for demographic and clinical details). Of the
1615 patients, 18 were excluded from the analyses because base-
line NRS was not available. A total of 1432 patients (89.7%
from baseline) reached the end of the first month trial period
T1 and were eligible for the trial period early response effective-
ness analysis. One hundred and sixty-five patients had to be
excluded for different reasons (see figure 1). At T2 (3 months),
889 (55.6%) patients and at T3 (6 months), 593 patients
(37.1%) were included in the analysis (see figure 1). Reasons for
not including the remaining patients at T2 and T3 are detailed





















Table 1 Clinical and demographic data
Total population RR SP+PP
N (%) 1615 315 (19.5) 1035+261 (80.2)
Male (%) 766 (47.4) 147 (46.6) 617 (47.6)
Female (%) 849 (52.6) 168 (53.3) 679 (52.4)
Age (years, mean±SD) 51±9.5 46.1±8.9 52±9.5*
Disease duration (years, mean±SD) 17.5±8.6 13.4±7.6 18.4±8.6*
Baseline EDSS (median, range) 6.5 (1.5–9.5) 5.0±1.3 6.7±0.9*
NRS score T0, Baseline (n=1597 pts, mean±SD) 7.5±1.4 7.4±1.5 7.6±1.4**
NRS score T1, month 1(n=1432 pts, mean±SD) 5.9±1.6 5.5±1.8 5.9±1.6
NRS T2, month 3 (n=889 pts, mean±SD) 5.1±1.6 4.9±1.8 5.2±1.5
NRS T3 month 6 (n=593 pts, mean±SD) 4.8±1.7 4.7±1.9 4.9±1.6
Dose, puffs number T1(mean±SD) 6.8±2.6 6.2±2.9 6.8±2.6
Dose, puffs number T2 (mean±SD) 6.5±2.6 6.2±2.9 6.5±2.6
Dose, puffs number T3 (mean±SD) 6.3±2.8 6.3±3.1 6.2±2.7
*p<0.0001; **p=0.0251.
EDSS, expanding disability status scale; NRS, numerical rating scale; PP, primary progressive; RR, relapsing remitting; SP, secondary progressive.
Figure 1 Patient flow chart. *Data not available at the specific time point.





















in figure 1. During the whole observation period, a total of 631
patients (39.5%) discontinued therapy.
Effectiveness outcome
The mean±SD 0–10 MS spasticity NRS score value at baseline
for the analysable 1597 patients was 7.5±1.4.
A statistically significant difference was found comparing the
baseline score with the different time points NRS score values
of the remaining patients. At T1, the NRS score was 5.9±1.6
(p<0.0001, n=1432), at T2 5.1±1.6 (p<0.0001, n=889) and
at T3 4.8±1.7 (p<0.0001, n=593; see table 1).
Within the 1432 patients who reached T1, end of trial
period, 4 weeks after treatment start, a total of 937 patients
(65.4%) were considered clinical responders according to the
treating specialist’s overall clinical judgement. One hundred and
thirty-three patients (9.3%) were considered partial responders
(suitable to become a responder in longer follow-up), whereas
349 patients (24.4%) were deemed to be non-responders. No
data were available for 16 patients (1.1%).
Regarding the NRS scale measurement of the MS spasticity
evolution, at T1 1010 patients (70.5%) reached a ≥20% NRS
score reduction compared with baseline (IR threshold), and 405
(28.3%) had already reached a≥30% NRS reduction (CRR). We
found a 22.6% reduction of mean NRS score at T1 compared
with baseline (n=1432). Within the T1 IR patients subgroup,
we found a 30.3% NRS score mean reduction at T1; and con-
sidering T1 CRR patients, we found a 40.8% NRS score mean
reduction at T1 (figure 2).
A total of 889 patients reached the 3 months’ visit T2, which
is 84.4% of those who might have reached it on the basis of the
treatment start date, n=1053. They showed a mean NRS score
of 7.5±1.5 at baseline and 5.1±1.6 at T2 (32% mean NRS
reduction). A total of 779 patients maintained scores ≥the IR
threshold at T2 (88% of patients reaching this visit and 73.9%
of those who should have reached it), with a mean NRS reduc-
tion of 31.6% at T2 compared with baseline (7.6±1.5 vs 5.2
±1.4). Three-hundred and eleven patients reached the CRR
threshold at T2 (35% of those reaching the visit and 29.5% of
those who should have reached it) with a mean NRS reduction
of 41.5% versus baseline (7.7±1.5 vs 4.5±1.4).
A total of 593 patients were available for analysis at the T3
sixth months’ control visit (73% of those who might have
reached it according to start date, n=811). Their mean±SD MS
spasticity 0–10 NRS score at T0 was 7.4±1.5, and we found a
reduction of 35% at T3 compared with baseline (T3 NRS mean
score 4.8±1.7). Five hundred and twenty-two maintained at
least a ≥IR threshold score at T3 (88% of patients reaching this
visit and 64.4% of those who could have reached it) with a
mean NRS reduction of 33.3% (7.5±1.5 at T0 vs 5±1.5 at T3).
Considering the CRR population (n=252, 42.5% of patients
reaching this visit and 31% of those who could have reached it),
we found a mean NRS reduction of 43.4% (7.6±1.5 vs 4.3
±1.5; see figure 3).
Regarding the medication dose, the mean number of puffs
per day was 6.8±2.6 at T1 and decreased to 6.5±2.6 at T2
(p=0.007) and 6.3±2.8 at T3 (p=0.0001; see table 1).
Univariate analysis logistic regression showed a significant
association between baseline NRS score and MS type and the
probability to reach IR at T1 (see table 2).
At a multivariate analysis, an age-adjusted and sex-adjusted sig-
nificant association with MS course and baseline NRS was
found. In particular, according to the multivariate analysis, we
found an increased probability to reach IR at T1 among patients
with secondary progressive primary progressive (SP-PP) (progres-
sive) MS (n=1169, OR 1.4 95% CI 1.05 to 1.86, p=0.018) and
among patients with higher spasticity NRS score (>8) at baseline
(n=358, OR 1.8 95% CI 1.4 to 2.4, p<0.001; see table 2).
Reasons for discontinuation
The number of patients who discontinued therapy during the
observation period was 631 (39.5%). Of them, 396 patients
(24.8% from the overall sample) did not reach the IR threshold.
Three hundred and seventy-four patients (23.4% of the overall
sample) discontinued after the 4-week trial period. Reasons for
discontinuation during the whole observation period were (mul-
tiple answers possible) lack of effectiveness (n=371, 23.2%,
mostly early), AEs (n=260, 16.3%), non-adherence (n=12,
0.8%), loss at follow-up (n=7, 0.4%) patient’s choice (n=5,
0.3%) or reasons not available (n=32, 2%).
Figure 2 Multiple sclerosis spasticity NRS evolution between T0 and
T1. NRS, numerical rating scale.
Figure 3 Multiple sclerosis spasticity NRS evolution between T0 and
T3. NRS, numerical rating scale.






















AE leading to discontinuation (18.7% of patients reaching T1,
1432 patients) were basically cognitive/psychiatric disturbances
(n=55, 3.9% of patients), in particular, out of the 55 cognitive/
psychiatric AEs, 9 were cognitive (3 attention deficit, 3 memory
impairment, 3 cognitive worsening) and 46 were psychiatric (32
confusional state, 9 panic attack/anxiety disorder, 3 hallucina-
tions, 1 depressive syndrome, 1 suicidal thoughts). Fatigue
(n=36, 2.5%), drowsiness (n=32, 2.2%), dizziness (n=30, 2%),
gastrointestinal symptoms (n=21, 1.4%), mouth discomfort
(n=10, 0.7%), allergic reaction (n=3, 0.2%) and other neuro-
logical symptoms (n=16, 1.1%) were other reported AEs, all
considered drug-related by clinicians. Data were not available
for n=100 (7%). No abuse, addiction or misuse hints were
detected. These AEs were considered drug-related. Of 268
patients, 260 discontinued treatment after the onset of AE (see
table 3). All patients recovered after discontinuation, the
remaining eight being kept on Sativex treatment. We found five
patients (0.3% of patients) presenting with a SAE: a hyperten-
sive crisis, one death after acute myocardial infarction, an acute
renal failure in a patient with chronic kidney disease, a laryngeal
carcinoma case and a breast cancer case. All these SAEs were
deemed to be unrelated to the study drug.
DISCUSSION
In this large multicentre study, we found that 70.5% of patients
reached the IR threshold and that 28.2% had already reached
the CRR threshold at the end of the 4-week trial period.
According to the physician’s judgement, 65.4% of patients were
considered responders after the first month of treatment, align-
ing with the proportion of patients reaching IR (70.5%),
whereas 9.3% were considered partial responders, suitable to
become responders in a longer follow-up.
We also found in patients reaching T1 (n=1432) a 22.6%
mean NRS spasticity score reduction at T1 (first month) and a
35% mean NRS score reduction at T3 (6 months) compared
with baseline, showing a decrease in NRS score from 7.5 at
baseline to 5.8 at T1 and 4.8 at T3. Considering the IR popula-
tion, we found a mean 30.3% reduction at T1 and a 33.3%
reduction at T3. Considering the CRR group, we found a
40.8% reduction at T1 and 43.4% reduction at T3. These data
suggest that a meaningful MS spasticity NRS reduction is
obtained during the first month and that it is maintained or
slightly increased over time (see the T3 6-month follow-up
data). This is in line with previous observational studies.16 19 20
It is noteworthy that the mean number of puffs decreased
slightly from 6.8 at T1 to 6.3 at T3, suggesting that effectiveness
may be maintained with lower doses compared to clinical trials
(mean number of 8.1 puffs/die in clinical trials),12 while ruling
out the need to increase dose to maintain effect over time (toler-
ance) and even abuse/misuse trends.
A certainly higher proportion of patients in our study reached
the IR ≥20% threshold in the first month (70.4%) when





N=422 OR 95% CI p Value
Sex
Women (%) 540 (53.5) 214 (50.7) 1 NA NA
Men (%) 469 (46.4) 208 (49.3) 0.89 0.7 to 1.1 0.324
Age (years, mean. Median=51) 50.8±9.6 51.2±9.6 0.99 0.98 to 1.0 0.471
18/51 539 (53.4) 242 (57.3) 1 NA NA
51/99 471 (46.6) 180 (42.6) 0.98 0.78 to 1.23 0.893
Disease duration (years, mean. Median=17) 17.8±8.6 17.4±8.6 1.0 0.99 to 1.01 0.416
0/17 518 (51.3) 212 (50.2) 1 NA NA
>17 492 (48.7) 210 (49.8) 0.93 0.74 to 1.17 0.552
EDSS (years, mean. Median=6.5) 6.5±1.1 6.5±1.2 1.02 0.92 to 1.12 0.686
0–6.5 607 (60) 245 (58) 1 NA NA
>6.5 403 (39.9) 177 (41.9) 0.97 0.77 to 1.22 0.806
Multiple sclerosis type
Relapsing remitting 188 (18.6) 74 (17.5) 1 NA NA
Secondary progressive and primary progressive 822 (81.4) 348 (82.4) 1.4 1.05 to 1.86 0.018
NRS (score, mean. Median=8) 7.6±1.4 7.3±1.5 1.2 1.1 to 1.3 <0.001
4/8 752 (74.5) 322 (76.3) 1 NA NA
>8 258 (25.5) 100 (23.7) 1.8 1.4 to 2.4 <0.001
EDSS, expanding disability status scale; IR, initial response; NA, not applicable; NRS, numerical rating scale.
Table 3 AE leading to discontinuation in the population reaching
T2 (n=1432)
Adverse events N (%)
Cognitive disturbances 9 (0.6)




Gastrointestinal symptoms 21 (1.4)
Mouth discomfort 10 (0.7)
Allergic reaction 3 (0.2)
Other neurological symptoms 16 (1.1)
Not available 100 (7)
SAE 5 (0.3)
AE, adverse event; SAE, serious adverse event.





















compared with patients from the German MOVE 2 study
(41.7%). However, in the German study, clinicians reported
observing clinical relief of resistant spasticity in 74.6% of
patients in the first month of treatment according to their own
judgement, in line with the results of our study (70.4%).16 In
Italy The AIFA e-registry requires an IR threshold attained after
the 4- week trial period to continue with the THC:CBD pre-
scription, obtained through an automatic calculation and within
a strict time frame. In other countries (Germany included), the
NRS improvement is calculated by the clinician without the use
of a compulsory web-based registry, thus possibly affecting the
perceptions of the initial response. This is confirmed by another
recent observational Italian study, showing that a proportion of
71.7% reached the IR with a mean NRS score reduction of
32%, in line with our results.20 The German MOVE 2 study IR
patients’ subgroup showed a mean reduction of NRS score of
40.2% at T1, while in our study a lower mean reduction,
30.3%, was observed. Considering the CRR ≥30% spasticity
NRS change versus baseline threshold patients subgroup evolu-
tion, a somehow larger mean reduction of 49.9% was observed
at T1 in Germany,16 while our results showed a mean reduction
of 40.8% in this subgroup. In a phase 3 randomised placebo-
controlled study, participants were also treated with THC:CBD
as an add-on therapy in a single-blind manner for 4 weeks.
After 4 weeks, 47.5% of patients reached IR, showing a MS
spasticity mean NRS score reduction of 47.6% compared with
baseline NRS, higher than the MOVE 2 observational study
score of 41.7% but still lower than our 70.4% rate.12 Our
results showed a higher proportion of IR responders but a
smaller mean change in term of NRS between baseline and T1,
not fully in accordance with previous studies, although in line
with recent findings from an observational Italian study.20 This
could in part be explained by the AIFA web registry features,
not allowing an NRS score <4 at baseline and always requiring
the IR threshold to be reached at the trial period follow-up
visit, thus affecting the recording of the improvement. Indeed,
our population seems to be more impaired, in terms of mean
EDSS and NRS scores, and has a longer disease duration, when
compared with other studies (see table 4). This could in part be
explained by multivariate analysis findings showing that reach-
ing the trial period IR threshold could be influenced by a base-
line NRS score and disease course (progressive MS). The
effectiveness of Sativex on patients with progressive MS spasti-
city has been investigated by a recent study evaluating clinical
and neurophysiological effects of treatment. Although no effect
on a neurophysiological measure (H reflex) was reported, the
study confirmed the clinical benefit (as per the Modified
Ashworth scale) in patients with progressive MS, affected by
lower limb spasticity.21
This finding may in part be related to the higher percentage
of SP and PP compared to relapsing remitting in our study
population (80% PP+SP), suggesting that patients with progres-
sive MS are more prone to have a spasticity not responding to
common anti-spastic drugs, requiring Sativex treatment.
Moreover, we found that patients with progressive MS are
older, and have a longer disease duration and higher EDSS and
NRS at baseline, suggesting that these differences might in part
have biased our findings (see table 1). As in our cohort, it was
recently reported that severe spasticity is more frequently
observed in wheelchair users while patients able to walk
300–500 m reported a mild to moderate spasticity.7 On these
grounds, it is conceivable that patients with a higher NRS score
and those with progressive MS could be more satisfied with any
improvement in their condition, while patients with lower EDSS
scores and thus better walking ability are more demanding in
terms of symptoms improvement. Indeed, we should bear in
mind that the use of symptomatic treatment is logically mainly
based on patients’ reported outcomes, rather than on neuro-
logical signs examination. However, replication and further ana-
lyses are required to better clarify our findings.
About 40% of our population discontinued treatment, in par-
ticular 26.2% discontinued for lack of effectiveness and 18.7%
for AEs. The most common AEs reported by patients were cog-
nitive/psychiatric effects, fatigue and drowsiness, in line with the
tolerability profile reported in other observational
studies.14 16 19
Although this is the largest study reporting Sativex experience
in daily clinical practice, our results may be affected by the
observational nature of the study. This could in part be miti-
gated by the use of the AIFA prospective and mandatory e-
registry as a source for spasticity NRS information and main
patient features. Indeed, in the Italian e-registry, the evaluations
are scheduled at 4 weeks from treatment start and then every
3 months, giving us the opportunity to collect data from every
centre at the same time points. Another limitation is the lack of
spasticity evaluation through the Ashworth healthcare profes-
sional impression categorical scale. Although the use of the
Ashworth Scale for the assessment of spasticity could be not
valid and reliable, results from the German MOVE 2 Study and
a recent clinical trial indicated a small but significant
improvement.16
Finally, the follow-up period duration (up to 6 months) may
be insufficient to assess Sativex effectiveness, safety and toler-
ability long-term effects.
Besides the aforementioned limitations, this study is the
largest multicentre observational study so far available evaluat-
ing Sativex effectiveness and tolerability profile in clinical prac-
tice. Our results confirm Sativex as an effective and safe option
for patients with MS with moderate to severe spasticity resistant
to common antispastic drugs. Longer and large multicentre
follow-up studies are needed to evaluate treatment effectiveness
Table 4 Sativex in a former observational study and clinical trial








N 300 pts 572 pts 1597
Male 132 225 766
Female (%) 168 (60.9) 347 (61) 849 (52.6%)




Baseline EDSS 6.0 (1–9)* 6.0±1.42† 6.5 (1.5–9.5)*
NRS T0 in IR (mean±SD) 6.4±1.8 6.9±1.2 7.6±1.4




IR after 1 month 42% 47% 70.5%
CRR after 3 months 41% 36% 28.3%






CRR, clinical relevant response (30% NRS response); EDSS, expanded disability status
scale; IR, initial response (20% NRS response); NRS, numerical rating scale for
multiple sclerosis spasticity.





















and tolerability effect in the population with MS. Further
exploitation of the AIFA Sativex e-registry data would be
desirable.
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